U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07478523) titled 'FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers' on March 12.
Brief Summary: Pancreatic cancer is one of the worst-prognosed cancers with a 5-year survival rate of less than 10%. Its incidence has been steadily increasing for several years in France and worldwide. Pancreatic adenocarcinoma may become the second leading cause of cancer mortality in the years 2030-2040. Current standard of care for pancreatic cancer imaging at initial workup comprise CT imaging and MRI. However, these imaging modalities lack sensitivity and accuracy, with an estimated rate of about 30% of patients either with visceral or ly...